Exact Sciences Corporation

EXAS

US30063P1057

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 01:41:46 2025-07-14 pm EDT			5-day change	1st Jan Change
53.63 ^USD	+3.31%		+2.25%	-4.50%

Jul. 09	Tariff Drama, Minimal Market Reaction
Jul. 09	Exact Sciences Says Its Oncodetect Test to Detect Colorectal Cancer Gets Medicare Coverage	MT

Exact Sciences Announces Expanded Clinical Validation Of Oncodetect Test And Molecular Residual Disease Innovation Roadmap

Published on 05/28/2025 at 07:41

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Exact Sciences Corporation

Tariff Drama, Minimal Market Reaction	Jul. 09
Exact Sciences Says Its Oncodetect Test to Detect Colorectal Cancer Gets Medicare Coverage	Jul. 09	MT
Exact Sciences Announces Medicare Coverage for Oncodetect Molecular Residual Disease Test in Colorectal Cancer	Jul. 09	CI
Exact Sciences announces Medicare coverage for Oncodetect(TM) molecular residual disease	Jul. 09	RE
Exact Sciences Corporation, Q1 2025 Earnings Call, May 01, 2025	Jul. 08
Gilead shares rise after US top court ruling on preventive coverage	Jun. 27	RE
Gilead shares rise after US top court ruling on preventive coverage	Jun. 27	RE
Exact Sciences Corporation Presents at 45th Annual William Blair Growth Stock Conference, Jun-03-2025 08:40 AM	Jun. 03
Exact Sciences Announces Expanded Clinical Validation of the Oncodetect? Test and Molecular Residual Disease Innovation Roadmap	May. 28	CI
Exact Sciences Announces Expanded Clinical Validation Of Oncodetect Test And Molecular Residual Disease Innovation Roadmap	May. 28	RE
Exact Sciences Corp. Highlights Innovations in Early Cancer Detection and Precision Oncology at ASCO 2025	May. 22	CI
Exact Sciences Corporation Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 10:40 AM	May. 14
US FDA approves first at-home test for cervical cancer screening	May. 09	RE
RBC Raises Price Target on Exact Sciences to $54 From $52, Keeps Sector Perform Rating	May. 02	MT
Exact Sciences Q1 Adjusted Loss Narrows, Revenue Rises; Shares Up	May. 01	MT
Earnings Flash (EXAS) Exact Sciences Posts Q1 Loss $-0.21 Per Share, vs. FactSet Est of $-0.25	May. 01	MT
Earnings Flash (EXAS) Exact Sciences Posts Q1 Revenue $706.8M, vs. FactSet Est of $688.6M	May. 01	MT
Exact Sciences Corporation Revises Earnings Guidance for the Year 2025	May. 01	CI
Exact Sciences Corporation Reports Unaudited Consolidated Impairment of Long-Lived and Indefinite-Lived Assets for the First Quarter Ended Mar. 31, 2025	May. 01	CI
Exact Sciences Corporation Reports Earnings Results for the First Quarter Ended March 31, 2025	May. 01	CI
Exact Sciences Corporation Appoints Leslie Trigg as A Class II Member of the Board	Apr. 29	CI
Exact Sciences Launches the Oncodetect Molecular Residual Disease Test	Apr. 22	CI
Exact Sciences Corp. Announces Publication of Comprehensive Review in JAMA Oncology That Strengthens the Evidence Supporting the Oncotype DX Breast Recurrence Score Test	Apr. 14	CI
Mizuho Initiates Exact Sciences at Outperform With $60 Price Target	Apr. 10	MT
Exact Sciences Corp. Launches the Cologuard Plus?? Test, Transforming Colorectal Cancer Screening	Mar. 31	CI

Chart Exact Sciences Corporation

Duration

Period

EXAS: Dynamic Chart

Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The Company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening, MCED Test Development and MRD Test Development. The Companyâs products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, and OncoExTra Test. The Companyâs flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patientâs breast tumor tissue.

Employees

6,950

Sector

Biotechnology & Medical Research

Calendar

Aug. 04 - Q2 2025 Earnings Release (Projected)

More about the company